cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Alnylam Pharmaceuticals Inc
9 own
12 watching
Current Price
$146.93
$-3.13
(-2.09%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
25,816.91M
52-Week High
52-Week High
218.88000
52-Week Low
52-Week Low
141.98000
Average Volume
Average Volume
0.74M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization25,816.91M
icon52-Week High218.88000
icon52-Week Low141.98000
iconAverage Volume0.74M
iconDividend Yield--
iconP/E Ratio--
What does the Alnylam Pharmaceuticals Inc do?
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. Its pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis (ATTR); Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia. Its early stage clinical programs include Givosiran that is in Phase I trial to treat acute hepatic porphyrias; ALN-CC5 for the treatment of complement-mediated diseases; ALN-GO1 to treat primary hyperoxaluria 1; ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; and ALN-HBV for the treatment of Hepatitis B virus. The company has strategic alliances and collaboration agreements primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc.; The University of British Columbia; and Acuitas Therapeutics Inc.; and Arbutus Biopharma Corporation. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Alnylam Pharmaceuticals Inc make?
News & Events about Alnylam Pharmaceuticals Inc.
Business Wire
11 months ago
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has set a date of September 13, 2023 for the...
Ticker Report
1 year ago
Research analysts at Sumitomo Mitsui Financial Group began coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY Get Rating) in a report released on Wednesday, Marketbeat reports. The brokerage set a neutral rating and a $220.00 price target on the biopharmaceutical ...
Benzinga
1 year ago
read more...
Insider Monkey
1 year ago
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2022 Earnings Call Transcript February 23, 2023 Operator: Thank you for standing by and welcome to the Alnylam Pharmaceuticals Fourth Quarter 2022 Financial Results Conference Call. As a reminder todays conference call is being recorded. I would now ...
Business Wire
1 year ago
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2022 and reviewed recent business highlights. 2022 was another year of strong progress at Alnylam, including...
Frequently Asked Questions
Frequently Asked Questions
What is Alnylam Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Alnylam Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Alnylam Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Alnylam Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Alnylam Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Alnylam Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Alnylam Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Alnylam Pharmaceuticals Inc?
plus_minus_icon
What percentage is Alnylam Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Alnylam Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$146.93
$-3.13
(-2.09%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00